TITLE

Methylnaltrexone: the evidence for its use in the management of opioid-induced constipation

AUTHOR(S)
Deibert, Peter; Xander, Carola; Blum, Hubert E.; Becker, Gerhild
PUB. DATE
January 2009
SOURCE
Core Evidence;2009, Vol. 4 Issue 1, p247
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Introduction: Constipation is a distressing side effect of opioid treatment, being so irksome in some cases that patients would rather suffer the pain than the side effect of opioid analgesics. Stool softeners or stimulating laxatives are often ineffective or even aggravate the situation. A new efficacious and safe drug is needed to limit the frequently observed side effects induced by effective opioid-based analgesic therapy and to improve the quality of life for patients, most of whom are impaired by a severe disease. Aims: The purpose of this article is to assess current evidence supporting the use of the peripherally acting ì-opioid receptor antagonist, methylnaltrexone, to restrict passage across the blood-brain barrier in patients with opioid-induced bowel dysfunction. Evidence review: There are now convincing data from phase II and multicenter phase III randomized, double-blind, placebo-controlled trials that methylnaltrexone induces laxation in patients with long-term opioid use without affecting central analgesia or precipitation of opioid withdrawal. Onset of the effect is rapid and improvement is maintained for at least 3 months during the drug treatment. The action of methylnaltrexone is dose dependent. Weight-related dosing appeared to be effective. There were no severe side effects or signs of opioid withdrawal. Adverse events, most frequently abdominal cramping or nausea, were usually mild to moderate. Methylnaltrexone is contraindicated in patients with known or suspected mechanical intestinal stenosis. Patients receiving methylnaltrexone must be monitored. Place in therapy: Methylnaltrexone applied subcutaneously every other day may be given to patients suffering from chronic constipation due to opioid therapy for whom laxatives do not provide adequate relief of their symptoms.
ACCESSION #
70338894

 

Related Articles

  • Desvenlafaxine in major depressive disorder: an evidence-based review of its place in therapy. Lieberman, Daniel Z.; Massey, Suena H. // Core Evidence;2009, Vol. 4 Issue 1, p67 

    Introduction: Desvenlafaxine, the active metabolite of venlafaxine, is a serotonin norepinephrine reuptake inhibitor (SNRI) recently approved for the treatment of major depressive disorder. It is one of only three medications in this class available in the United States. Aims: The objective of...

  • Luliconazole for the treatment of fungal infections: an evidence-based review. Khanna, Deepshikha; Bharti, Subhash // Core Evidence;2014, Vol. 9, p113 

    Abstract: Luliconazole is an imidazole antifungal agent with a unique structure, as the imidazole moiety is incorporated into the ketene dithioacetate structure. Luliconazole is the R-enantiomer, and has more potent antifungal activity than lanoconazole, which is a racemic mixture. In this...

  • Effects of Expiratory Muscle Strength Training on Videofluoroscopic Measures of Swallowing: A Systematic Review. Mancopes, Renata; Smaoui, Sana; Steele, Catriona M. // American Journal of Speech-Language Pathology;Feb2020, Vol. 29 Issue 1, p335 

    Purpose: Expiratory muscle strength training (EMST) is increasingly utilized in dysphagia rehabilitation; however, little is known about the effects of this approach on swallowing function or physiology. We conducted a systematic review to appraise and synthesize evidence regarding the effects...

  • Complementary feeding and developmental milestones: a systematic review. English, Laural K; Obbagy, Julie E; Wong, Yat Ping; Butte, Nancy F; Dewey, Kathryn G; Fox, Mary Kay; Greer, Frank R; Krebs, Nancy F; Scanlon, Kelley S; Stoody, Eve E // American Journal of Clinical Nutrition;2019 Supplement, Vol. 109, p879S 

    Background Systematic reviews were conducted as part of the USDA and the US Department of Health and Human Services Pregnancy and Birth to 24 Months Project to examine the relation between complementary feeding and developmental milestones. Objectives The aim of this study was to describe...

  • Occupational Therapy for Adults with Overweight and Obesity: Mapping Interventions Involving Occupational Therapists. Nielsen, Svetlana Solgaard; Christensen, Jeanette Reffstrup // Occupational Therapy International;10/30/2018, p1 

    Background. Worldwide obesity rates are increasing. The effectiveness of occupational therapy in overweight and obese adults has not yet been clarified. Objectives. The scoping review aimed at examining the evidence on interventions involving occupational therapists in the treatment of adults...

  • Chocolate consumption and cardiometabolic disorders: systematic review and meta-analysis. Buitrago-Lopez, Adriana; Sanderson, Jean; Johnson, Laura; Warnakula, Samantha; Wood, Angela; Di Angelantonio, Emanuele; Franco, Oscar H. // BMJ: British Medical Journal (Overseas & Retired Doctors Edition;10/1/2011, Vol. 343 Issue 7825, p679 

    The article reports on a study based on the consumption of chocolate and its impact on cardiometabolic disorders. It informs that these disorders include cardiovascular disease, myocardial infarction, stroke and ischaemic heart disease. It also states that high level of consumption of chocolate...

  • Use of Nalbuphine for Treatment of Neuraxial Opioid-Induced Pruritus: A Systematic Review and Meta-Analysis. Tubog, Tito D. // AANA Journal;Jun2019, Vol. 87 Issue 3, p222 

    Opioid-induced pruritus is prevalent after neuraxial administration of opioid. A number of preventive measures have been reported; however, only a few studies evaluated treatment strategies for established pruritus. The pharmacokinetics and pharmacodynamic profiles of nalbuphine make this drug...

  • Ustekinumab: an evidence-based review of its effectiveness in the treatment of psoriasis. Krulig, Eliana; Gordon, Kenneth B. // Core Evidence;2010, Vol. 5 Issue 1, p11 

    Introduction: Psoriasis is a chronic inflammatory skin disease affecting approximately 2% to 3% of the population worldwide. Discoveries over the past 3 to 5 years have significantly altered our view of psoriasis as primarily a T-cell mediated condition. The most recent research has demonstrated...

  • Trabectedin: the evidence for its place in therapy in the treatment of soft tissue sarcoma. Thornton, Katherine A. // Core Evidence;2009, Vol. 4 Issue 1, p191 

    Introduction: Soft tissue sarcoma accounts for less than 1% of all malignant neoplasms and is comprised of a very heterogeneous group of tumors with over 50 different subtypes. Due to its diversity and rarity, developing new therapeutics has been difficult, at best. The standard of care in the...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics